The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 12:15 PM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #51. Sangamo BioSciences Ceregene

Acquirer: Sangamo BioSciences (NASDAQ:SGMO)
Acquiree: Ceregene
Details: Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.

Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO SEC Filing Email Alerts Service


Open the SGMO Page at The Online Investor »

Company Name: 
Sangamo Therapeutics Inc
Website: 
www.sangamo.com
Sector: 
Biotechnology
Number of ETFs Holding SGMO: 
29
Total Market Value Held by ETFs: 
$79.05M
Total Market Capitalization: 
$607.00M
% of Market Cap. Held by ETFs: 
13.02%
 

Open the SGMO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree SGMO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.43 out of 4)
42nd percentile
(ranked lower than approx. 58% of all stocks covered)

Analysts' Target Price:
SGMO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 51 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.